Gynecologic Cancer clinical trials at UCSF
2 research studies open to eligible people
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
open to eligible people ages 18 years and up
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with advanced solid tumors with certain mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors and breast cancer; Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with breast cancer. Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.
San Francisco, California and other locations
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
open to eligible females ages 18 years and up
This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.
San Francisco, California and other locations
Our lead scientists for Gynecologic Cancer research studies include Stephanie Cham, MD.
Last updated: